What is the recommended dosing of Tranexamic acid (TXA) for the treatment of menorrhagia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Tranexamic acid should be dosed at 1,000-1,300 mg orally three times daily for menorrhagia, as this regimen has been shown to significantly reduce menstrual blood loss. When considering treatment options for menorrhagia, it is essential to weigh the benefits and risks of each medication.

  • Tranexamic acid works by inhibiting fibrinolysis, which helps stabilize blood clots and reduces heavy menstrual flow 1.
  • The medication can cause mild side effects, including nausea, vomiting, or diarrhea, and is contraindicated in women with active thromboembolic disease, history of thrombosis, or intrinsic risk for thrombosis 1.
  • According to the available evidence, tranexamic acid can reduce menstrual blood loss by approximately 40-60% and may be used alongside hormonal treatments if needed 1.
  • Patients should be advised to take the medication with food to minimize gastrointestinal side effects and to start treatment when bleeding begins, continuing until bleeding lessens, usually for no more than 5 days per menstrual cycle.
  • It is crucial to note that the medication should be used with caution in patients with renal impairment, requiring dose adjustment (reduced dose or frequency) if creatinine clearance is below 60 mL/min.
  • While other treatment options, such as NSAIDs, have been studied, the evidence for tranexamic acid is more robust, making it a preferred choice for menorrhagia treatment 1.

From the Research

Tranexamic Acid Dosing for Menorrhagia

  • The recommended dosage of tranexamic acid for menorrhagia varies, but common dosages include 1-1.5 g three times daily for 5 days 2, 3.
  • A study found that tranexamic acid 2-4.5 g/day for 4-7 days reduced menstrual blood loss by 34-59% over 2-3 cycles 2.
  • High doses of tranexamic acid, such as 3 grams daily in four divided doses for the first 5 days of the menstrual cycle, have been used to treat severe menorrhagia in patients with von Willebrand disease 4.
  • The efficacy of tranexamic acid in reducing menstrual blood loss has been demonstrated in several studies, with reductions in blood loss ranging from 34-59% 2 to 49% 3.
  • Tranexamic acid has been shown to be a safe and effective treatment for menorrhagia, with few adverse events reported 2, 3, 5.

Comparison to Other Treatments

  • Tranexamic acid has been compared to other treatments for menorrhagia, including mefenamic acid, flurbiprofen, etamsylate, and oral luteal phase norethisterone, and has been found to be more effective in reducing menstrual blood loss 2.
  • Levonorgestrel IUD has been found to be more effective than tranexamic acid in reducing menstrual blood loss, but may have a higher incidence of adverse events such as intermenstrual bleeding 2, 6.
  • Tranexamic acid has been recommended as a first-line treatment for idiopathic menorrhagia, especially for patients in whom hormonal treatment is contraindicated or not desired 2, 6.

Patient Response and Quality of Life

  • Studies have shown that tranexamic acid can improve quality of life in patients with menorrhagia, with reductions in impairment during menstruation and improvements in hematological parameters 3, 5.
  • The response rate to tranexamic acid treatment has been reported to be around 65-81% in different studies 3, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of idiopathic menorrhagia with tranexamic acid.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005

Research

Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause.

European journal of obstetrics, gynecology, and reproductive biology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.